Clinical Trials /

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

NCT03712904

Description:

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

Related Conditions:
  • Uveal Melanoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
  • Official Title: Phase II Randomized Trial of Stereotactic Radiotherapy (SRT) Followed by Intravitreal Aflibercept Injection for Patients With Ocular Melanoma

Clinical Trial IDs

  • ORG STUDY ID: 18P.457
  • NCT ID: NCT03712904

Conditions

  • Uveal Melanoma

Interventions

DrugSynonymsArms
Ziv-Aflibercept724770, 862111-32-8, AVE0005, Eylea, Vascular Endothelial Growth Factor TrapB. Stereotactic body radiation therapy, ziv-aflibercept

Purpose

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To assess the percentage of patients able to successfully complete their prescribed
      treatment of radiation and intravitreal ziv-aflibercept (aflibercept) injection (IAI) with an
      acceptable level of toxicity.

      SECONDARY OBJECTIVES:

      I. To assess for reduction in the incidence of 2-year rates of radiation maculopathy,
      radiation papillopathy, functional vision preservation, radiation glaucoma, and to assess
      2-year local control and progression-free survival.
    

Trial Arms

NameTypeDescriptionInterventions
A. Stereotactic body radiation therapy, ziv-afliberceptExperimentalPatients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
    B. Stereotactic body radiation therapy, ziv-afliberceptExperimentalPatients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
    • Ziv-Aflibercept

    Eligibility Criteria

            Inclusion Criteria:
    
              -  Provide signed and dated informed consent form or have a Legally Authorized
                 Representative (LAR) who can give consent
    
              -  Willing to comply with all study procedures and be available for the duration of the
                 study
    
              -  Must be a candidate for radiation therapy
    
              -  Karnofsky performance status (KPS) >= 60
    
              -  Diagnosed with uveal melanoma either clinically or pathologically on biopsy
    
              -  Uveal melanoma of one eye only
    
              -  Localized uveal melanoma, with no evidence of metastasis
    
              -  Women of childbearing potential must have a negative urine or serum pregnancy test
                 within 14 days prior to enrollment
    
            Exclusion Criteria:
    
              -  Tumor thickness more than 14 mm as measured by ultrasound
    
              -  Active collagen vascular disease
    
              -  Any contraindication to intravitreal injections including: elevated intraocular
                 pressure, ocular or periocular infection, active intraocular inflammation, or other
                 determined by treating physician
    
              -  Known allergic reactions to components of intravitreal Aflibercept
    
              -  Patients with known hypercoagulable syndromes
    
              -  Prior radiation to the eye or brain
    
              -  Life expectancy less than 6 months
    
              -  Blind in both eyes
    
              -  Patients unable to receive contrast enhanced brain magnetic resonance imaging (MRI)
    
              -  Deaf in both ears
    
              -  Patients have hypersensitivity to intravitreal Aflibercept
    
              -  Patients is on or within 1 month of systemic anti-VEGF treatment
    
              -  Patients who are candidates for brachytherapy
    
              -  Patients for whom enucleation is standard of care
    
              -  Pregnancy or active breastfeeding. Sexually active men or women of childbearing
                 potential who are unwilling to practice adequate contraception prior to the initial
                 dose/start of the first treatment, during the study, and for at least 3 months after
                 the last dose. Adequate contraceptive measures include stable use of oral
                 contraceptives or other prescription pharmaceutical contraceptives for 2 or more
                 menstrual cycles prior to screening; intrauterine device; bilateral tubal ligation;
                 vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus
                 contraceptive sponge, foam, or jelly
    
                   -  Contraception is not required for men with documented vasectomy
    
                   -  Postmenopausal women must be amenorrheic for at least 12 months in order not to
                      be considered of childbearing potential. Pregnancy testing and contraception are
                      not required for women with documented hysterectomy or tubal ligation
          
    Maximum Eligible Age:N/A
    Minimum Eligible Age:18 Years
    Eligible Gender:Female
    Healthy Volunteers:Accepts Healthy Volunteers

    Primary Outcome Measures

    Measure:Incidence of grade 3 or higher toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
    Time Frame:Up to 2 years
    Safety Issue:
    Description:Will be determined by patients who experience grade >= 3 toxicity related to stereotactic radiation therapy and/or intravitreal aflibercept. Will be tested using one-sided exact binomial test with alpha 0.05. The two arms will be combined for the primary analysis

    Secondary Outcome Measures

    Measure:Radiation maculopathy rate defined as ophthalmoscopic detection of macular edema perivascular sheathing
    Time Frame:At 2 years
    Safety Issue:
    Description:Will be estimated separately in each arm with the corresponding exact binomial 90% confidence interval.
    Measure:Radiation papillopathy rate defined as ophthalmoscopic detection of peripapillary encircling nerve fiber layer infarction
    Time Frame:At 2 years
    Safety Issue:
    Description:Will be estimated separately in each arm with the corresponding exact binomial 90% confidence interval.

    Details

    Phase:Phase 2
    Primary Purpose:Interventional
    Overall Status:Recruiting
    Lead Sponsor:Sidney Kimmel Cancer Center at Thomas Jefferson University

    Last Updated

    August 19, 2019